Shots:

• Merck KGaA to receive $4.2B as total deal value- including $341.76M upfront- up to $3.8B milestones including R&D- regulatory and commercialization. GSK to get worldwide co-development and co-commercialization rights for Merck’s M7824 with 50/50 profit/cost sharing
• The focus of the agreement is to strengthen GSK’s oncology portfolio in areas of immuno-oncology- cell therapy- cancer epigenetics and genetic medicine
• Merck’s M7824 (bintrafusp alfa) is a bifunctional immunotherapy targeting TGF-β trap with anti-PD-L1 mechanism and is evaluated in P-I/II vs pembrolizumab in 700 patients with PD-L1 expressing advanced NSCLC

Ref: GSK | Image: GSK